The combined application of pharmacokinetic and pharmacodynamic models to concentration and effect observations can be used to predict the consequences of alternative dosing strategies. Efficient experimental design is intimately related to the models that may be employed for data analysis. This is especially important in phase I studies which provide the basis for decisions on future clinical trials.